Cargando…
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, fo...
Autores principales: | Saussele, Susanne, Hehlmann, Rüdiger, Fabarius, Alice, Jeromin, Sabine, Proetel, Ulrike, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Einsele, Hermann, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Oppliger Leibundgut, Elisabeth, Heim, Dominik, Krause, Stefan W., Hofmann, Wolf-Karsten, Hasford, Joerg, Pfirrmann, Markus, Müller, Martin C., Hochhaus, Andreas, Lauseker, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940636/ https://www.ncbi.nlm.nih.gov/pubmed/29479070 http://dx.doi.org/10.1038/s41375-018-0055-7 |
Ejemplares similares
-
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
por: Kalmanti, Lida, et al.
Publicado: (2013) -
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022) -
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020) -
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020) -
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)